Welcome to Friends’ third Quarterly Advocacy Newsletter of 2024. In Q3, Friends published several peer-reviewed manuscripts with insights on enhancing representation in clinical trials, use of RWD to assess response to treatment, and opportunities for pragmatic elements to be incorporated in clinical trials supporting regulatory decisions. We’re excited to share details on these publications and…
Chevron deference was established by the 1984 Supreme Court of the United States (SCOTUS) case of Chevron, U.S.A., Inc. v. Natural Resources Defense Council, Inc., which related to EPA’s ability to regulate air quality under the Clean Air Act. The decision mandated that federal courts defer to federal agency’s reasonable interpretation of ambiguous statutes…
Friends of Cancer Research (Friends) is pleased to announce the publication of our new perspective on the significance of pragmatic clinical trials (PCTs) in ESMO Real World Data and Digital Oncology. PCTs evaluate the effectiveness of interventions in settings that more closely resemble real-world care, aiming to produce evidence directly applicable to clinical practice. Recognizing…
Testimony for the hearing noted the recent authorities provided through the Food and Drug Omnibus Reform Act of 2022 (FDORA) designed to enhance the accelerated approval program and ensure timely generation of confirmatory evidence.
Welcome to Friends’ second Quarterly Advocacy Newsletter of 2024. In Q2, Friends co-hosted a public meeting about cell therapies with the Parker Institute for Cancer Immunotherapy, published several peer-reviewed manuscripts, and launched a webpage for patients and advocates, including a section about our Advisory Advocates. We’re so excited to share these and other happenings at…
Chris White is a passionate advocate for cell therapies. He spends his time collaborating with patient advocacy groups, philanthropy organizations, and industry stakeholders focused on melanoma and cell therapy.
On May 23rd, Friends of Cancer Research hosted a public webinar, “Friends’ Cell Therapies Webinar for Advocates,” spotlighting the pivotal role of patient advocacy and cell and gene therapies in cancer care. Dr. Alex Marson from Gladstone Institutes presented CRISPR’s potential in cancer immunotherapy, while Chris White, author and patient advocate, shared his journey with metastatic melanoma and the success of a tumor-infiltrating lymphocytes (TIL) therapy trial, emphasizing the impact of cell therapies in remission. The webinar bridged the gap between research and tangible patient outcomes by facilitating an open dialogue and an engaging Q&A session between the live audience and panelists.
While significant progress has been made in cancer treatment and care, this progress has not always easily translated to new treatments for pediatric oncology patients. In 2003, the Pediatric Research Equity Act (PREA) passed requiring the study of cancer therapeutics in certain pediatric cases.
On May 6th, Friends of Cancer Research and Parker Institute for Cancer Immunotherapy hosted a public meeting, “Unlocking Complex Cell-Based Therapies,” to discuss innovative frameworks and proposals for enhancing the safety, expansion, and activity of the next generation of cell-based gene therapies. Panels addressed operational and biological challenges to advancing cell and gene therapies, novel approaches to clinical trials, the expansion of cell therapies for solid tumors, and included patient insights and experiences with these complex therapies.
On February 15th, Friends of Cancer Research hosted a virtual public meeting, “Enhancing Diversity in Clinical Trials: Implementation of Diversity Plans,” emphasizing the importance of ensuring diverse representation in clinical trials to promote health equity, minimize biases, and foster holistic approaches in scientific research.
